Kevin Koch
Directeur Général chez EDGEWISE THERAPEUTICS, INC.
Fortune : 6 M $ au 30/06/2024
Profil
Kevin Koch was the founder of Array BioPharma, Inc. (founded in 1998) where he held the title of President & Chief Scientific Officer from 2012 to 2013.
He is currently the President, Chief Executive Officer & Director at Edgewise Therapeutics, Inc. since 2017.
He is also a Director at Encycle Therapeutics, Inc., Neurogastrx, Inc., Skyhawk Therapeutics, Inc., Terremoto Biosciences, Inc., and a Venture Partner at OrbiMed Advisors Private Equity since 2016.
Dr. Koch previously worked as an Associate Director-Medicinal Chemistry at Amgen, Inc. from 1995 to 1998, Director at Inflammation Research Association, Inc. from 1998 to 2003, Director at Ataxion, Inc., Independent Director at Viridian Therapeutics, Inc. from 2017 to 2020, and Senior Vice President at Biogen, Inc. from 2013 to 2015.
He also worked as a Senior Research Investigator at Pfizer Inc. from 1988 to 1995.
Dr. Koch holds a doctorate degree from Rochester Christian University and an undergraduate degree from Stony Brook University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/05/2024 | 353 262 ( 0,38% ) | 6 M $ | 30/06/2024 |
Postes actifs de Kevin Koch
| Sociétés | Poste | Début |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Directeur Général | 01/01/2017 |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Private Equity Investor | 01/05/2016 |
Encycle Therapeutics, Inc.
 Encycle Therapeutics, Inc. BiotechnologyHealth Technology Encycle Therapeutics, Inc. provides biotechnology services. It offers rapid synthesis of drug-like macrocycles or membrane-permeable nacellins which have enormous potential to target intracellular protein-protein interactions. The company was founded by Andrei Yudin is headquartered in Toronto, Canada. | Directeur/Membre du Conseil | - |
Neurogastrx, Inc.
 Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Directeur/Membre du Conseil | 04/01/2018 |
Skyhawk Therapeutics, Inc.
 Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Directeur/Membre du Conseil | - |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Anciens postes connus de Kevin Koch
| Sociétés | Poste | Fin |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 28/10/2020 |
| BIOGEN INC. | President | 01/09/2015 |
| ARRAY TECHNOLOGIES, INC. | Fondateur | 29/11/2013 |
| ░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Kevin Koch
| Stony Brook University | Undergraduate Degree |
| Rochester Christian University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| EDGEWISE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Inflammation Research Association, Inc.
 Inflammation Research Association, Inc. Miscellaneous Commercial ServicesCommercial Services Inflammation Research Association, Inc. engages in encouraging scientists, researchers, students, teachers and clinicians with an interest in inflammation biology. The company is headquartered in Newcastle, WA. | Commercial Services |
Ataxion, Inc.
 Ataxion, Inc. BiotechnologyHealth Technology Ataxion, Inc. develops novel therapies for rare, debilitating, and underserved neurologic diseases. It focuses on orphan genetic disorders termed hereditary ataxias. It was founded by Josh Resnick and David Grayzel in April 2013 and is headquartered in Cambridge, MA. | Health Technology |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
Encycle Therapeutics, Inc.
Encycle Therapeutics, Inc. BiotechnologyHealth Technology Encycle Therapeutics, Inc. provides biotechnology services. It offers rapid synthesis of drug-like macrocycles or membrane-permeable nacellins which have enormous potential to target intracellular protein-protein interactions. The company was founded by Andrei Yudin is headquartered in Toronto, Canada. | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Health Technology |
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Health Technology |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Health Technology |
